These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 34179333)

  • 1. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
    Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
    Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
    Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
    Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
    Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.
    Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S
    JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy.
    Kim HM; Kim KH; Park JS; Oh BH
    Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33922990
    [No Abstract]   [Full Text] [Related]  

  • 19. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.